Treatment of Systemic Mastocytosis with Recurrent Hypotension in Indolent or Smoldering Disease
Clinical Scenario
This protocol addresses patients with indolent or smoldering systemic mastocytosis (ISM/SSM) who experience recurrent hypotension — an episodic complication requiring specific management alongside general disease control.
Key Considerations
In ISM and smoldering systemic mastocytosis, recurrent hypotension drives the need for targeted intervention. Treatment goals are primarily directed toward anaphylaxis prevention, symptom control, and management of related complications.
Treatment Approach — Partial Overview
First-line management focuses on a specific emergency pharmacological agent to address acute hypotensive episodes. The complete protocol — including its use, sequencing, and supporting measures — is available in the full structured regimen.
References
DOI: 10.1002/ajh.26962
- Treatment goals for ISM patients are primarily directed toward anaphylaxis prevention/symptom control/osteoporosis treatment.
- Epinephrine — See text
View source ↗